Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cgh.2024.07.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The impact of cancer expectations on psychological responses following a cancer signal detected result in asymptomatic multi-cancer detection (MCED) testing.
Br J Cancer
September 2025
Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, E1 1HH, UK.
Background: Multi-cancer detection (MCED) blood tests have the potential to screen for early-stage cancers. Understanding how people experience an MCED cancer signal result is vital prior to any future implementation. We explored experiences in a trial context.
View Article and Find Full Text PDFCase Report: Multi-cancer early detection utilizing blood-based genomics: Single-institution case series of novel cancer screening.
Front Oncol
August 2025
Department of Radiation Medicine, Oregon Health & Science University, Portland, OR, United States.
Purpose/objectives: Cancer screening continues to be a major challenge, with reliable tests only being available for very few cancers. Multi-cancer early detection (MCED) genomic tests are being developed that allow for blood-based screening of multiple cancers simultaneously. The PATHFINDER study was a multi-institution prospective cohort study in healthy participants over the age of 50 years (no cancer history, or history of treated cancer > 3 years prior), investigating the feasibility of the Galleri (GRAIL, LLC) cfDNA methylation MCED blood test.
View Article and Find Full Text PDFImpact of Population Cancer Risk on the Cost-effectiveness of Multi-cancer Early Detection Testing in the US.
Cancer Epidemiol Biomarkers Prev
August 2025
University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
Background: Cancer remains a significant global health challenge, particularly for subpopulations with risk factors including genetic predisposition, comorbidities, and lifestyle, along with age. The Galleri® multi-cancer early detection (MCED) test is projected to be cost-effective for individuals aged ≥50 years. However, its potential value in subpopulations with elevated cancer risk remains underexplored.
View Article and Find Full Text PDFA multivariate cell-based liquid biopsy for lung nodule risk stratification: Analytical validation and early clinical evaluation.
J Liq Biopsy
September 2025
PreCyte, Inc., Seattle, WA, USA.
Background: The Indicator Cell Assay Platform (iCAP) is a novel tool for blood-based diagnostics that uses living cells as biosensors to integrate and amplify weak, multivalent disease signals present in patient serum. In the platform, standardized cells are exposed to small volumes of patient serum, and the resulting transcriptomic response is analyzed using machine learning tools to develop disease classifiers.
Methods: We developed a lung cancer-specific iCAP (LC-iCAP) as a rule-out test for the management of indeterminate pulmonary nodules detected by low-dose CT screening.
Oxypalmatine promotes apoptosis and protective autophagy in lung cancer cells via the PI3K/AKT pathway.
Cancer Cell Int
August 2025
Medical School of Nantong University, Nantong, Jiangsu, China.
Unlabelled: Oxypalmatine (OPT), a small molecule alkaloid isolated from Phellodendron amurense, is a bioactive compound with promising anticancer potential. We evaluated the efficacy of OPT using four lung adenocarcinoma cell lines and four patient-derived organoid tissues. Additionally, the anticancer effects of OPT were further validated through in vivo experiments.
View Article and Find Full Text PDF